Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.
AuthID
P-00R-HSN
P-00R-HSN